Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2...
Read More »Twist Bioscience expands offering of synthetic SARS-CoV-2 RNA controls for NGS diagnostics
Twist announced the addition of four new synthetic SARS-CoV-2 RNA Controls for the development, verification, and ongoing validation of diagnostic tests. The controls include new variants of SARS-CoV-2, the virus that causes COVID-19...
Read More »